

THE role of endogenously synthesized PAF and prostaglandins on the infection of mouse macrophages by *Leishmania (L.) amazonensis* was investigated, as well as the possible correlation between the effects of these inflammatory mediators with nitric oxide production. It was found that pretreatment of macrophages with 10^{-5} M of the PAF antagonists, BN-52021 or WEB-2086, increased macrophage infection by 17 and 59%, respectively. The cyclooxygenase inhibitor, indomethacin ($10 \mu\text{g/ml}$), induced a significant inhibition which was reversed by addition of PGE_2 (10^{-5} M) to the culture medium. These results suggested that the infection of macrophages by *Leishmania* is inhibited by PAF and enhanced by prostaglandins and that these mediators are produced by macrophages during this infection. This was confirmed by addition of these mediators to the culture medium before infection; PAF (10^{-6} , 10^{-9} and 10^{-12} M) reduced significantly the infection whereas PGE_2 (10^{-5} M) induced a marked enhancement. This effect of exogenous PAF on macrophage infection was reversed by the two PAF antagonists used in this study as well as by the inhibitor of nitric oxide synthesis, L-arginine methyl ester (100 mM). Taken together the data suggest that endogenous production of PAF and PGE_2 exert opposing effects on *Leishmania*–macrophage interaction and that nitric oxide may be involved in the augmented destruction of parasites induced by PAF.

Key words: Leishmaniasis, *Leishmania (L.) amazonensis*, Macrophage infection, PAF, Prostaglandins

Modulation of *Leishmania (L.) amazonensis* growth in cultured mouse macrophages by prostaglandins and platelet activating factor

M. V. C. Lonardoni,¹ C. L. Barbieri,²
M. Russo³ and S. Jancar^{3,CA}

¹Department of Biochemistry, Universidade Estadual de Maringá, Paraná;

²Department of Microbiology, Immunology and Parasitology, Escola Paulista de Medicina, São Paulo; ³Department of Immunology, Instituto de Ciências Biomédicas, Universidade de São Paulo, Av. Prof. Lineu Prestes 2415, CEP 05508-900, São Paulo, Brazil

CA Corresponding Author

Introduction

Species from the *Leishmania* genus are protozoans which present two forms during their life cycle, promastigotes which live in the digestive tract of the insect vector and amastigotes, obligate intracellular parasites which replicate in macrophages of their vertebrate hosts.

It has been shown that lymphokine activated mouse macrophages present an increased nitrite production which correlates with increased leishmanicidal activity of these cells.^{1–3} It seems that production of nitric oxide (NO) is more important than superoxide in the intracellular parasite killing.⁴ *Leishmania* destruction was shown to be completely reversed by structural analogues of L-arginine which inhibit NO production.^{1–3} Conversely, parasite killing can proceed normally in a macrophage cell line deficient in the respiratory burst⁴ and Kupffer cells which do not display an oxidative burst in response to *Leishmania*.⁵ However, Andrade *et al.* showed that in the early phase of infection, a very low number of T cells is present at the site of inoculation of *Leishmania* in contrast to a massive influx of macrophages which rapidly take up the parasites.⁶ Thus, it is unlikely that macrophage activation medi-

ated by T cells would occur at this stage of infection. It is more plausible to think that macrophage responses induced by the parasite would influence the course of the disease. Indeed, Barcinski *et al.*⁷ presented evidence that granulocyte–macrophage colony stimulating factor, a macrophage product, increases the infectivity of *Leishmania amazonensis* by protecting promastigotes from heat-induced death. A possible role for prostaglandins in the exacerbation of the disease in *L. major*-infected BALB/c mice was suggested by Farrell and Kirkpatrick.⁸ It has been shown that an increased production of PGE_2 , $\text{PGF}_{2\alpha}$, LTC_4 , TXB_2 and PGD_2 occurs during the course of murine infection with *L. donovani*.^{9,10}

The lipid inflammatory mediators derived from arachidonic acid metabolism (eicosanoids) and PAF (platelet activating factor) may exert important autocrine effects on macrophages. Prostaglandins of the E series increase cAMP^{11–13} and by this mechanism they modulate several macrophage functions.¹⁴ PAF is an important amplifier of biological processes in several cell types. In macrophages, PAF inhibits expression of class II molecules,¹⁵ modulates IL-1 production in LPS-stimulated monocytes¹⁶ and stimulates TNF production.¹⁷ To date, PAF involvement in *Leishmania* infection has not been reported.

The purpose of the present study was to investigate the role of endogenously produced prostaglandins and PAF in *in vitro* infection of mouse macrophages with *L. (L.) amazonensis*. Macrophages of BALB/c mice were infected with *L. (L.) amazonensis* amastigotes and the phagocytic index was determined in presence and absence of PAF antagonists, WEB-2086 or BN-52021, and an inhibitor of prostaglandin synthesis, indomethacin. The effect of PAF and PGE₂ added to the culture medium was also investigated. The possible involvement of NO was studied by using L-arginine methyl ester (L-NAME) and an inhibitor of NO synthesis.

Materials and Methods

Animals: BALB/c mice (20–30 g) and outbred Golden hamsters 2–3 months old from our own animal facilities were used.

Isolation of *L. (L.) amazonensis* amastigotes from hamster foot pads: *L. (L.) amazonensis* amastigotes (10⁷ parasites/ml) were transferred every 4 to 6 weeks to hamsters by inoculation into foot pads. Amastigote suspensions were prepared by homogenization of excised lesions in RPMI 1640 medium containing 10% foetal calf serum (FCS) with a Potter glass homogenizer and the parasites separated by centrifugation at 1 400 × g for 10 min.

Macrophage cultures and *L. (L.) amazonensis* infection: Macrophages were collected in phosphate buffered saline (PBS) from peritoneal cavities of BALB/c mice. About 4 × 10⁵ cells were allowed to attach to round 13 mm glass coverslips. The non-adherent cells were removed by rinsing the coverslips with PBS. Coverslips were placed in 16 mm diameter wells of Costar plates containing 0.5 ml of RPMI 1640 plus 10% FCS, 100 U of penicillin and 100 µg of streptomycin per ml and kept in a 5% CO₂ humid atmosphere at 37°C. After 24 h, *L. (L.) amazonensis* amastigotes were added to the macrophage monolayers at a cell ratio of 3 parasites/macrophage at 37°C. At different times after infection, the coverslips were washed with PBS, the cells fixed in absolute methanol for 10 min and stained with Giemsa, dried, mounted on glass slides and examined microscopically.

Results were expressed by phagocytic index which is the product of the percentage of infected macrophages times the average number of amastigotes per macrophage.

Evaluation of nitric oxide production: Nitrite is an oxidation product formed by nitric oxide in an aqueous solution. The nitrite concentration was measured in the culture supernatant media by the method previously described by Green *et al.*² Briefly, 50 µl aliquots of samples in triplicate were added to 50 µl

of Griess reagent in 96-well flat-bottomed plates. The absorbance was read at 550 nm (Dynatech MR5000) after 10 min of reaction and NO₂⁻ concentration was deduced from a standard curve using concentrations from 1 to 5 µM of sodium nitrite in culture media.

Drug treatments: Indomethacin (10 µg/ml) prepared in Tris-HCl (1 M, pH 8.0) was added to the macrophage culture medium 24 h before infection. The PAF antagonists, WEB-2086 and BN-52021, were added to the culture medium 1 h before infection and every 12 h thereafter at concentrations ranging from 10⁻⁵ to 10⁻⁷ M. The diluent for BN-52021 was provided by the drug company and WEB-2086 was dissolved in PBS. The agonists PAF (10⁻⁶, 10⁻⁹ and 10⁻¹² M) and PGE₂ (10⁻⁵ M) were added to the culture medium at the moment of infection. PAF and PGE₂ were supplied in ethanol and were further diluted in saline containing 0.25% BSA and PBS, respectively. The concentration of ethanol in the culture medium never exceeded 0.1%. The effect of all diluents used was assayed. At the concentrations used, the drugs did not significantly affect macrophage viability as assessed by the Trypan blue exclusion test.

Drugs and reagents: Cell culture medium (RPMI 1640), indomethacin, L-glutamine, penicillin, streptomycin and N-omega-nitro-L-arginine methyl ester hydrochloride (L-NAME) were all purchased from Sigma Chem. Co. (USA); PGE₂ from UpJohn Co. (USA) and PAF from Bachem (Switzerland). BN-52021 and WEB-2086 were kindly supplied by Institut Henri Beaufour (France) and Boehringer-Ingelheim (Germany), respectively.

Statistical analysis: Student's *t*-test for paired samples and analysis of variance were used to evaluate the significance of the data (*p* < 0.01).

Results

Effect of endogenous PAF and prostaglandins on *L. (L.) amazonensis* infected macrophages: In order to investigate the role of endogenously generated PAF and prostaglandins in *L. (L.) amazonensis* macrophage infection, the macrophages were treated with either the PAF antagonists (BN-52021 or WEB-2086) or the cyclooxygenase inhibitor (indomethacin) before infection, and the phagocytic index was determined 48 h later. The two antagonists were added to the culture medium 1 h before infection and every 12 h thereafter while indomethacin was added 24 h before infection. The results obtained (Fig. 1) show that pre-treatment of macrophages with BN-52021 or WEB-2086 significantly increased the macrophage infection (17.3 and 59.4% increase, respectively). Indomethacin, however, induced a significant inhibition. Addition of PGE₂ (10⁻⁵ M) to indomethacin-treated macrophages reversed this inhibition.




FIG. 1. Effect of endogenous PAF and prostaglandins on *L. (L.) amazonensis* infected macrophages. Mouse peritoneal macrophages treated with indomethacin (10 $\mu\text{g/ml}$), BN-52021 (10^{-5}M), WEB-2086 (10^{-5}M) and indomethacin + PGE₂ (10^{-5}M) before infection with *L. (L.) amazonensis* amastigotes. Indomethacin and the PAF antagonists were added to the culture medium 24 and 1 h before infection, respectively. The phagocytic index was determined 48 h later. The controls represent the values obtained in non-treated macrophages. The results were obtained by counting at least 200 macrophages per duplicate coverslip. Error bars show standard deviations of three experiments (* $p < 0.01$ compared with the non-treated group).

Table 1 shows that WEB-2086 increased the infection dose dependently, a maximum potentiation being achieved with 10^{-5}M , although at 10^{-6} and 10^{-7}M the drug was also significantly effective. The control group treated with the diluents of the drugs did not differ from the non-treated group.

Effect of exogenous PAF and PGE₂ on L. (L.) amazonensis infected macrophages: The results obtained with the PAF antagonists and indomethacin suggest that PAF and prostaglandins endogenously generated modulate the *in vitro* infection. In order to evaluate whether addition of PAF or PGE₂ to the culture medium influence the infection, these mediators were added to the culture medium at the moment of infection and the phagocytic index determined 48 h later. The results obtained show that PAF (10^{-6} , 10^{-9} and 10^{-12}M) reduced the infection dose dependently whereas PGE₂ (10^{-5}M) induced a marked enhancement (Fig. 2). In some experiments PAF was added to culture medium 24 h before infection. In this case it caused 26.5 and 74.6% of inhibi-

Table 1. Effect of WEB-2086 on the infection of macrophages by *L. (L.) amazonensis*

Concentration of WEB-2086 (M)	Time after infection (h)		
	24	48	72
Control	249.31 \pm 9.03	408.91 \pm 5.34	658.08 \pm 9.83
10^{-7}	388.83 \pm 7.27* (55.96)	505.06 \pm 21.80* (23.51)	563.71 \pm 11.85* (14.34)
10^{-6}	412.97 \pm 5.80* (57.95)	577.30 \pm 7.18* (36.08)	722.26 \pm 8.80* (18.62)
10^{-5}	492.43 \pm 14.71* (88.34)	696.72 \pm 16.51* (64.23)	850.87 \pm 17.90* (39.76)

Phagocytic index obtained in macrophages infected with *L. (L.) amazonensis* in the absence (Control) or presence of WEB-2086, added to the culture medium 1 h before infection. Data represent the mean \pm S.E.M. of three experiments in duplicate. * $p < 0.01$ compared with the group treated with the diluent. Data in brackets represent the percentage of enhancement.




FIG. 2. Effect of exogenous PAF and PGE₂ on *L. (L.) amazonensis* infected macrophages. Mouse peritoneal macrophages treated with PAF (10^{-12} , 10^{-9} and 10^{-6}M) and PGE₂ (10^{-5}M) at the moment of infection with *L. (L.) amazonensis* amastigotes and phagocytic index determined 48 h later. Non-treated macrophages were used as control. The results were obtained by counting at least 200 macrophages per duplicate coverslip. Error bars show standard deviations of six experiments (* $p < 0.01$ compared with the non-treated group).

Table 2. Effect of PAF antagonists on the PAF induced inhibition of macrophages infection by *L. (L.) amazonensis* amastigotes

Group	Treatment ^a	Agonist ^b (10 ⁻⁶ M)	Phagocytic index ^c
I	—	—	425.57 ± 10.26
II	—	PAF	125.17 ± 2.36*
III	BN-52021 (10 ⁻⁵ M)	PAF	223.88 ± 7.76**
IV	WEB-2086 (10 ⁻⁵ M)	PAF	181.95 ± 4.44**

^aThe antagonists were given 1 h before infection.

^bPAF was added at the moment of infection.

^cThe phagocytic index was determined 48 h after infection of macrophages with *L. (L.) amazonensis*.

Data represent the mean ± S.E.M. of three experiments in duplicate

* $p < 0.01$ compared with group I.

** $p < 0.01$ compared with group II.

tion at 10⁻⁹ and 10⁻⁶ M, respectively. At 10⁻¹² M it was no longer effective. The control groups treated with diluents of PAF and PGE₂ did not differ from the non-treated group.

Effect of PAF antagonists on PAF induced inhibition of *L. (L.) amazonensis* macrophage infection: The ability of PAF antagonists to inhibit the PAF induced effect




FIG. 3. Effect of L-NAME on PAF induced inhibition of *L. (L.) amazonensis* macrophage infection. Mouse peritoneal macrophages pretreated for 1 h with L-NAME (100 μM) followed by administration of PAF (10⁻⁶ M) at the moment of infection with *L. (L.) amazonensis* amastigotes. Phagocytic index was determined 48 h later. The results were obtained by counting at least 200 macrophages per triplicate coverslip. Error bars show standard deviations of three experiments (* $p < 0.01$ compared with the non-treated group).

was investigated. Macrophages were treated with 10⁻⁵ M of the antagonists BN-52021 or WEB-2086, 1 h before addition of PAF at 10⁻⁶ M concentration to the culture medium and the phagocytic index was determined 48 h later. Results presented in Table 2 confirmed that PAF induced a marked inhibition of the phagocytic index and showed that both PAF antagonists were able to significantly reverse this effect.

Effect of L-NAME on PAF induced inhibition of *L. (L.) amazonensis* macrophage infection: The effect of L-NAME was studied in combination with PAF. The macrophages were treated with L-NAME, 1 h before addition of PAF (10⁻⁶ M) and parasites to the culture medium and the phagocytic index was determined 48 h later. Controls were carried out by treating the macrophages with either L-NAME or PAF alone. Fig. 3 shows that the inhibitory effect of PAF on the *L. (L.) amazonensis* macrophage infection was reversed by 100 mM L-NAME. This figure also shows that L-NAME increased the phagocytic index of macrophages treated with or without PAF. In addition, we assayed the NO release in the supernatants. The concentration of nitrites/nitrates in these supernatants was below the detection limit allowed by the assay employed (data not shown). The efficacy of L-NAME to inhibit NO production was tested on macrophages from BCG infected mice. It was found that BCG-activated macrophages released 0.929 ± 0.054 nmol of NO/10⁵ peritoneal cells after 48 h in culture medium and that pre-treatment of macrophages with 100 mM of L-NAME significantly inhibited this production (0.402 ± 0.018 nmol/10⁵ peritoneal cells).

Discussion

In leishmaniasis, as in other intracellular parasite infections, macrophages are both the host and the effector cell. Several studies focused on the influence of T cells and their products on macrophages activation which would lead either to healing or exacerbation of the disease (for review see Locksley and Scott¹⁸). However, few studies have analysed the consequences of the initial interaction between macrophage and parasites on parasite multiplication.

In the present work we showed that treatment of macrophages with indomethacin, an inhibitor of prostaglandins synthesis, before infection with *L. (L.) amazonensis* significantly inhibited parasite growth. This result indicates that prostaglandins are released by macrophages during the infection and that they favour parasite survival possibly by inhibiting activation of the macrophage. Since the effect of indomethacin was reversed by the addition of PGE₂ to the culture medium, it is likely that this cyclooxygenase metabolite is the one responsible for the observed effect. Our findings are in agreement with those reported by Buchmüller-Rouiller *et al.*¹⁹

showing that PGE₂ inhibits the leishmanicidal activity of macrophages activated with ionophore and LPS.

That macrophages are able to produce prostaglandins when infected with *Leishmania* has been shown by studies *in vitro* and *in vivo*.^{9,10} Prostaglandin E₂ is known to exert negative feedback on macrophage activation,²⁰ an effect probably mediated by an increased intracellular level of cAMP.¹⁹ In our model, it is probable that prostaglandins generated by the infected macrophages inhibited their capacity to control parasite multiplication. In support of this assumption it has been shown that treatment of susceptible BALB/c mice infected with *L. major* with indomethacin significantly inhibited the number of metastatic lesions.⁸ However, this effect might not rely entirely on inhibition of macrophage function since prostaglandins also inhibit lymphocyte proliferation induced by Con A and parasite antigens.⁸

To study the role of PAF on this infection, two specific PAF antagonist, BN-52021²¹ or WEB-2086²² were added to the culture medium before infection with *L. (L.) amazonensis*. These treatments increased the phagocytic index indicating that PAF is generated endogenously by infected macrophages and in turn it exerts a marked inhibition of parasite growth. This was confirmed by experiments where PAF was added exogenously to culture medium of infected macrophages. In this case, a clear dose dependent inhibition of parasite multiplication was observed. We also showed that the doses of the PAF antagonists used in this study were effective to antagonize PAF receptors in murine macrophages since both antagonists were able to reverse the inhibitory effect of PAF.

It is known that macrophages can generate PAF when properly stimulated;¹⁷ however, to our knowledge this is the first report to show that PAF exerts such a relevant effect on leishmanial infection.

Another substance that is recognized as a potent leishmanicidal agent *in vivo* and *in vitro* is nitric oxide (for review see Liew and Cox²³). Thus, we reasoned whether the inhibitory effect of PAF on leishmanial growth could be mediated by NO. To this end we added an inhibitor of NO synthesis (L-NAME) to infected macrophages in the presence or absence of PAF. In both situations L-NAME increased parasite multiplication. These results, although indirect, strongly suggest the participation of NO as the active molecule that mediates the PAF induced macrophage leishmanicidal activity.

The present work showed that PGE₂ has a stimulatory effect whereas PAF has an inhibitory effect on *L. (L.) amazonensis* infection in mouse macrophages. It also showed that the leishmanicidal effect of PAF is mediated by NO. It will be of interest

to measure the levels of PGE₂ and PAF released by infected macrophages obtained from resistant and susceptible strains of mouse and also to determine the effect of these lipid mediators on the course of *in vivo* infection.

References

- Liew FY, Millott S, Parkinson C, Palmer RMJ, Moncada S. Macrophage killing of *Leishmania* parasite *in vivo* is mediated by nitric oxide from L-arginine. *J Immunol* 1990; **144**: 4794–4797.
- Green SJ, Meltzer MS, Hibbs Jr JB, Nacy CA. Activated macrophages destroy intracellular *Leishmania major* amastigotes by an L-arginine-dependent killing mechanism. *J Immunol* 1990; **144**: 278–283.
- Mauël J, Ransijn A, Buchmüller-Rouiller Y. Killing of *Leishmania* parasites in activated murine macrophages is based on an L-arginine-dependent process that produces nitrogen derivatives. *J Leuk Biol* 1991; **49**: 73–82.
- Scott P, James S, Sher A. The respiratory burst is not required for killing intracellular and extracellular parasites by a lymphokine-activated macrophage cell line. *Eur J Immunol* 1985; **15**: 553–558.
- Crocker PR, Davis EV, Blackwell JM. Variable expression of the murine natural resistance gene *Lsb* in different macrophage populations infected *in vitro* with *Leishmania donovani*. *Parasite Immunol* 1987; **9**: 705–719.
- Andrade ZA, Reed SG, Roters SB, Sadigursky M. Immunopathology of experimental cutaneous leishmaniasis. *Am J Pathol* 1984; **114**: 137–148.
- Barcinski MA, Schechtman D, Quinta, et al. Granulocyte-macrophage colony-stimulating factor increases the infectivity of *Leishmania amazonensis* by protecting promastigotes from heat-induced death. *Infect Immun* 1992; **60**: 3523–3527.
- Farrell JP, Kirkpatrick CE. Experimental cutaneous leishmaniasis. II. A possible role for prostaglandins in exacerbation of disease in *Leishmania major*-infected BALB/c mice. *J Immunol* 1987; **138**: 902–907.
- Reiner NE, Maledum CJ. Arachidonic acid metabolism in murine Leishmaniasis (*donovani*): *ex-vivo* evidence for increased cyclooxygenase and 5-lipoxygenase activity in spleen cells. *Cell Immunol* 1984; **88**: 501–510.
- Reiner NE, Maledum CJ. Arachidonic acid metabolism by murine peritoneal macrophages infected with *Leishmania donovani*: *in vitro* evidence for parasite-induced alterations in cyclooxygenase and lipoxygenase pathways. *J Immunol* 1985; **134**: 556–563.
- Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. *J Immunol* 1983; **3**: 295–297.
- Rincon M, Tugores A, Lopez-Rivas A, et al. Prostaglandin E and the increase of intracellular cAMP inhibit the expression of interleukin-2 receptors in human T cells. *Eur J Immunol* 1988; **18**: 1791–1794.
- Papadogiannakis N, Nordstrom TE, Anderson LC, Wolff CHJ. cAMP inhibits the OKT3-induced increase in cytoplasmic free calcium in the Jukart T cell line. *Eur J Immunol* 1989; **19**: 1953–1958.
- Minakuchi R, Wacholtz MC, Davis LS, Lipsky PE. Delineation of the mechanism of inhibition of human T-cell activation by PGE₂. *J Immunol* 1990; **145**: 2616–2625.
- Gehard BM, Bazan HEP, Bazan NG. BN 52021 blocks PAF-mediated suppression of cellular immunity. In: Braquet P, ed. *Ginkgolides—chemistry, biology, pharmacology and clinical perspectives*. Barcelona: Prous. Sci. Publish., 1988; 703–729.
- Pignol B, Henane S, Mencia-Huerta JM, Rola-Pleszczynski M, Braquet P. Effect of PAF-acether and its specific antagonist, BS 52021, on interleukin-1 synthesis and release by rat monocytes. *Prostaglandins* 1987; **33**: 391–397.
- Poubelle PE, Gingras D, Demers, et al. Platelet-activating factor (PAF-acether) enhances the concomitant production of tumor necrosis factor-alpha and IL-1 by subsets of human monocytes. *J Immunol* 1991; **72**: 181–187.
- Locksley RM, Scott P. Helper T-cell subsets in mouse leishmaniasis: induction, expansion and effector functions. *Immunol Today* 1991; **12**: A58–A61.
- Buchmüller-Rouiller Y, Betz-Corradini S, Mauël J. Differential effects of prostaglandins on macrophage activation induced by calcium ionophore or IFN-gamma. *J Immunol* 1992; **148**: 1171–1175.
- Schultz RM. Factors limiting tumoricidal functions of interferon-induced effector systems. *Cancer Immunol Immunother* 1978; **10**: 61–66.
- Braquet P, Godfroid JJ. PAF-acether specific binding sites. Design of specific antagonists. *Trends Pharmacol Sci* 1986; **7**: 397–403.
- Casals-Stenzel J, Muacevic R, Weber H. Pharmacological actions of WEB 2086, a new specific antagonist of PAF. *J Pharmacol Exp Therap* 1987; **241**: 947–981.
- Liew FY, Cox FEG. Nonspecific defence mechanism: the role of nitric oxide. *Immunol Today* 1991; **12**: A17–A21.

ACKNOWLEDGEMENTS. The authors thank Maria de Fátima Farias P. Carvalho and Dunia Rodriguez for technical assistance. This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) from Brazil.

**Received 22 November 1993;
accepted in revised form 3 January 1994**



Hindawi
Submit your manuscripts at
<http://www.hindawi.com>

